Novo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of "Hold" from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) have been assigned a consensus rating of "Hold" from the thirteen research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $135.00.

Several brokerages have commented on NVO. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Clark Capital Management Group Inc. raised its holdings in shares of Novo Nordisk A/S by 1.0% in the first quarter. Clark Capital Management Group Inc. now owns 319,142 shares of the company's stock valued at $22,161,000 after purchasing an additional 3,250 shares during the last quarter. Curi RMB Capital LLC raised its holdings in shares of Novo Nordisk A/S by 339.7% in the first quarter. Curi RMB Capital LLC now owns 51,146 shares of the company's stock valued at $3,597,000 after purchasing an additional 39,514 shares during the last quarter. Bridger Management LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $8,444,000. Banque Transatlantique SA grew its stake in shares of Novo Nordisk A/S by 85.8% in the first quarter. Banque Transatlantique SA now owns 8,938 shares of the company's stock valued at $574,000 after buying an additional 4,128 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock valued at $4,312,000 after buying an additional 10,758 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 4.2%

Shares of NYSE:NVO traded down $2.81 during mid-day trading on Tuesday, reaching $63.34. The stock had a trading volume of 9,585,178 shares, compared to its average volume of 6,515,028. The firm has a market cap of $284.24 billion, a PE ratio of 19.29, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The firm has a 50 day simple moving average of $67.59 and a two-hundred day simple moving average of $84.91. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.